Innate Immunity

Otolaryngologic Clinics of North America

Volumn 43, Issue 3, 2010, Pages 473-487

  Ooi, Eng H ^a   Psaltis, Alkis J ^b,c   Witterick, Ian J ^a   Wormald, Peter John ^b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b FLINDERS UNIVERSITY   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Biofilms; Cigarette smoke; Cystic fibrosis; Innate immunity; Rhinosinusitis; Toll like receptors

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; BETA DEFENSIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CORTICOSTEROID; DEXAMETHASONE; INTERLEUKIN 8; LACTOFERRIN; LIPOTEICHOIC ACID; LYSOZYME; PSEUDOMONIC ACID; SURFACTANT PROTEIN A; SURFACTANT PROTEIN D; TOBRAMYCIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4; TRANSMEMBRANE CONDUCTANCE REGULATOR; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; BACTERIAL COLONIZATION; BACTERIAL SINUSITIS; BACTERICIDAL ACTIVITY; BIOFILM; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CILIARY MOTILITY; CYSTIC FIBROSIS; ENDOSCOPIC SINUS SURGERY; FUNGAL SINUSITIS; FUNGICIDAL ACTIVITY; HUMAN; INNATE IMMUNITY; MUCOCILIARY CLEARANCE; MUCOSAL IMMUNITY; MUCUS SECRETION; NONHUMAN; NOSE POLYP; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; QUORUM SENSING; REVIEW; RHINOSINUSITIS; SMOKING CESSATION; STAPHYLOCOCCUS AUREUS;

BIOFILMS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; CYTOKINES; HOMEOSTASIS; HUMANS; IMMUNITY, INNATE; MUCOCILIARY CLEARANCE; MUCUS; POINT MUTATION; RHINITIS; SINUSITIS; TOLL-LIKE RECEPTORS;

EID: 77953489262     PISSN: 00306665     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.otc.2010.02.020     Document Type: Review

References (97)

1. Ooi E.H., Wormald P.J., Tan L.W. Innate immunity in the paranasal sinuses: a review of nasal host defenses. Am J Rhinol 2008, 22(1):13-19.
2. Bals R., Hiemstra P.S. Innate immunity in the lung: how epithelial cells fight against respiratory pathogens. Eur Respir J 2004, 23(2):327-333.
3. Lane A.P. The role of innate immunity in the pathogenesis of chronic rhinosinusitis. Curr Allergy Asthma Rep 2009, 9(3):205-212.
4. Benninger M.S., Ferguson B.J., Hadley J.A., et al. Adult chronic rhinosinusitis: definitions, diagnosis, epidemiology, and pathophysiology. Otolaryngol Head Neck Surg 2003, 129(Suppl 3):S1-32.
5. Anand V.K. Epidemiology and economic impact of rhinosinusitis. Ann Otol Rhinol Laryngol Suppl 2004, 193:3-5.
6. Metson R.B., Gliklich R.E. Clinical outcomes in patients with chronic sinusitis. Laryngoscope 2000, 110(3 Pt 3):24-28.
7. Van Cauwenberge P., Watelet J.B. Epidemiology of chronic rhinosinusitis. Thorax 2000, 55(Suppl 2):S20-S21.
8. Meltzer E.O., Hamilos D.L., Hadley J.A., et al. Rhinosinusitis: establishing definitions for clinical research and patient care. J Allergy Clin Immunol 2004, 114(6 Suppl):155-212.
9. Cohen M., Kofonow J., Nayak J.V., et al. Biofilms in chronic rhinosinusitis: a review. Am J Rhinol Allergy 2009, 23(3):255-260.
10. Seiberling K.A., Grammer L., Kern R.C. Chronic rhinosinusitis and superantigens. Otolaryngol Clin North Am 2005, 38(6):1215-1236. ix.
11. Sasama J., Sherris D.A., Shin S.H., et al. New paradigm for the roles of fungi and eosinophils in chronic rhinosinusitis. Curr Opin Otolaryngol Head Neck Surg 2005, 13(1):2-8.
12. Braun H., Buzina W., Freudenschuss K., et al. 'Eosinophilic fungal rhinosinusitis': a common disorder in Europe?. Laryngoscope 2003, 113(2):264-269.
13. Sanderson A.R., Leid J.G., Hunsaker D. Bacterial biofilms on the sinus mucosa of human subjects with chronic rhinosinusitis. Laryngoscope 2006, 116(7):1121-1126.
14. Kern R.C., Conley D.B., Walsh W., et al. Perspectives on the etiology of chronic rhinosinusitis: an immune barrier hypothesis. Am J Rhinol 2008, 22(6):549-559.
15. Kumar H., Kawai T., Akira S. Pathogen recognition in the innate immune response. Biochem J 2009, 420(1):1-16.
16. Lin C.F., Tsai C.H., Cheng C.H., et al. Expression of Toll-like receptors in cultured nasal epithelial cells. Acta Otolaryngol 2007, 127(4):395-402.
17. Dong Z., Yang Z., Wang C. Expression of TLR2 and TLR4 messenger RNA in the epithelial cells of the nasal airway. Am J Rhinol 2005, 19(3):236-239.
18. Lane A.P., Truong-Tran Q.A., Myers A., et al. Serum amyloid A, properdin, complement 3, and toll-like receptors are expressed locally in human sinonasal tissue. Am J Rhinol 2006, 20(1):117-123.
19. Rampey A.M., Lathers D.M., Woodworth B.A., et al. Immunolocalization of dendritic cells and pattern recognition receptors in chronic rhinosinusitis. Am J Rhinol 2007, 21(1):117-121.
20. Vanhinsbergh L.J., Powe D.G., Jones N.S. Reduction of TLR2 gene expression in allergic and nonallergic rhinitis. Ann Allergy Asthma Immunol 2007, 99(6):509-516.
21. Pitzurra L., Bellocchio S., Nocentini A., et al. Antifungal immune reactivity in nasal polyposis. Infect Immun 2004, 72(12):7275-7281.
22. Tan L., Rogers T.J., Hatzirodos N., et al. Immunomodulatory effect of cytosine-phosphate-guanosine (CpG)-oligonucleotides in nonasthmatic chronic rhinosinusitis: an explant model. Am J Rhinol Allergy 2009, 23(2):123-129.
23. Fokkens W., Lund V., Mullol J. European position paper on rhinosinusitis and nasal polyps 2007. Rhinol Suppl 2007, 20:1-136.
24. Wise S.K., Kingdom T.T., McKean L., et al. Presence of fungus in sinus cultures of cystic fibrosis patients. Am J Rhinol 2005, 19(1):47-51.
25. Pinto J.M., Hayes M.G., Schneider D., et al. A genomewide screen for chronic rhinosinusitis genes identifies a locus on chromosome 7q. Laryngoscope 2008, 118(11):2067-2072.
26. Wang X., Kim J., McWilliams R., et al. Increased prevalence of chronic rhinosinusitis in carriers of a cystic fibrosis mutation. Arch Otolaryngol Head Neck Surg 2005, 131(3):237-240.
27. Raman V., Clary R., Siegrist K.L., et al. Increased prevalence of mutations in the cystic fibrosis transmembrane conductance regulator in children with chronic rhinosinusitis. Pediatrics 2002, 109(1):E13.
28. Doring G., Gulbins E. Cystic fibrosis and innate immunity: how chloride channel mutations provoke lung disease. Cell Microbiol 2009, 11(2):208-216.
29. Smith J.J., Travis S.M., Greenberg E.P., et al. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996, 85(2):229-236.
30. Cohen N.A. Sinonasal mucociliary clearance in health and disease. Ann Otol Rhinol Laryngol Suppl 2006, 196:20-26.
31. Messerklinger W. Monatsschr Ohrenheilkd Laryngorhinol 1966, 100(1-2):56-68. [in German].
32. Schenck N.L. Frontal sinus disease. III. Experimental and clinical factors in failure of the frontal osteoplastic operation. Laryngoscope 1975, 85(1):76-92.
33. Kennedy D.W. Functional endoscopic sinus surgery. Technique. Arch Otolaryngol 1985, 111(10):643-649.
34. Sakakura Y., Majima Y., Saida S., et al. Reversibility of reduced mucociliary clearance in chronic sinusitis. Clin Otolaryngol 1985, 10(2):79-83.
35. Elwany S., Hisham M., Gamaee R. The effect of endoscopic sinus surgery on mucociliary clearance in patients with chronic sinusitis. Eur Arch Otorhinolaryngol 1998, 255(10):511-514.
36. Inanli S., Tutkun A., Batman C., et al. The effect of endoscopic sinus surgery on mucociliary activity and healing of maxillary sinus mucosa. Rhinology 2000, 38(3):120-123.
37. Chen B., Shaari J., Claire S.E., et al. Altered sinonasal ciliary dynamics in chronic rhinosinusitis. Am J Rhinol 2006, 20(3):325-329.
38. Chen B., Antunes M.B., Claire S.E., et al. Reversal of chronic rhinosinusitis-associated sinonasal ciliary dysfunction. Am J Rhinol 2007, 21(3):346-353.
39. Maccabee M.S., Trune D.R., Hwang P.H. Paranasal sinus mucosal regeneration: the effect of topical retinoic acid. Am J Rhinol 2003, 17(3):133-137.
40. Briggs R.D., Wright S.T., Cordes S., et al. Smoking in chronic rhinosinusitis: a predictor of poor long-term outcome after endoscopic sinus surgery. Laryngoscope 2004, 114(1):126-128.
41. Houser S.M., Keen K.J. The role of allergy and smoking in chronic rhinosinusitis and polyposis. Laryngoscope 2008, 118(9):1521-1527.
42. Karaman M., Tek A. Deleterious effect of smoking and nasal septal deviation on mucociliary clearance and improvement after septoplasty. Am J Rhinol Allergy 2009, 23(1):2-7.
43. Dye J.A., Adler K.B. Effects of cigarette smoke on epithelial cells of the respiratory tract. Thorax 1994, 49(8):825-834.
44. Mehta H., Nazzal K., Sadikot R.T. Cigarette smoking and innate immunity. Inflamm Res 2008, 57(11):497-503.
45. Lan M.Y., Ho C.Y., Lee T.C., et al. Cigarette smoke extract induces cytotoxicity on human nasal epithelial cells. Am J Rhinol 2007, 21(2):218-223.
46. Lee W.K., Ramanathan M., Spannhake E.W., et al. The cigarette smoke component acrolein inhibits expression of the innate immune components IL-8 and human beta-defensin 2 by sinonasal epithelial cells. Am J Rhinol 2007, 21(6):658-663.
47. Tamashiro E., Xiong G., Anselmo-Lima W.T., et al. Cigarette smoke exposure impairs respiratory epithelial ciliogenesis. Am J Rhinol Allergy 2009, 23(2):117-122.
48. Cantin A.M., Hanrahan J.W., Bilodeau G., et al. Cystic fibrosis transmembrane conductance regulator function is suppressed in cigarette smokers. Am J Respir Crit Care Med 2006, 173(10):1139-1144.
49. Bajmoczi M., Gadjeva M., Alper S.L., et al. Cystic fibrosis transmembrane conductance regulator and caveolin-1 regulate epithelial cell internalization of Pseudomonas aeruginosa. Am J Physiol Cell Physiol 2009, 297(2):C263-C277.
50. MacRedmond R.E., Greene C.M., Dorscheid D.R., et al. Epithelial expression of TLR4 is modulated in COPD and by steroids, salmeterol and cigarette smoke. Respir Res 2007, 8:84.
51. Sims M.W., Tal-Singer R.M., Kierstein S., et al. Chronic obstructive pulmonary disease and inhaled steroids alter surfactant protein D (SP-D) levels: a cross-sectional study. Respir Res 2008, 9:13.
52. Psaltis A.J., Bruhn M.A., Ooi E.H., et al. Nasal mucosa expression of lactoferrin in patients with chronic rhinosinusitis. Laryngoscope 2007, 117(11):2030-2035.
53. Kalfa V.C., Spector S.L., Ganz T., et al. Lysozyme levels in the nasal secretions of patients with perennial allergic rhinitis and recurrent sinusitis. Ann Allergy Asthma Immunol 2004, 93(3):288-292.
54. Ooi E.H., Wormald P.J., Carney A.S., et al. Human cathelicidin antimicrobial peptide is up-regulated in the eosinophilic mucus subgroup of chronic rhinosinusitis patients. Am J Rhinol 2007, 21(4):395-401.
55. Lee S.H., Kim J.E., Lim H.H., et al. Antimicrobial defensin peptides of the human nasal mucosa. Ann Otol Rhinol Laryngol 2002, 111(2):135-141.
56. Ooi E.H., Wormald P.J., Carney A.S., et al. Surfactant protein D expression in chronic rhinosinusitis patients and immune responses in vitro to Aspergillus and Alternaria in a nasal explant model. Laryngoscope 2007, 117(1):51-57.
57. Woodworth B.A., Neal J.G., Newton D., et al. Surfactant protein A and D in human sinus mucosa: a preliminary report. ORL J Otorhinolaryngol Relat Spec 2007, 69(1):57-60.
58. Ramanathan M., Lee W.K., Lane A.P. Increased expression of acidic mammalian chitinase in chronic rhinosinusitis with nasal polyps. Am J Rhinol 2006, 20(3):330-335.
59. Singh P.K., Tack B.F., McCray P.B., et al. Synergistic and additive killing by antimicrobial factors found in human airway surface liquid. Am J Physiol Lung Cell Mol Physiol 2000, 279(5):L799-L805.
60. Cole A.M., Liao H.I., Stuchlik O., et al. Cationic polypeptides are required for antibacterial activity of human airway fluid. J Immunol 2002, 169(12):6985-6991.
61. De Y., Chen Q., Schmidt A.P., et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med 2000, 192(7):1069-1074.
62. Borron P.J., Mostaghel E.A., Doyle C., et al. Pulmonary surfactant proteins A and D directly suppress CD3+/CD4+ cell function: evidence for two shared mechanisms. J Immunol 2002, 169(10):5844-5850.
63. Haczku A. Protective role of the lung collectins surfactant protein A and surfactant protein D in airway inflammation. J Allergy Clin Immunol 2008, 122(5):861-879. [quiz: 880-1].
64. Postle A.D., Mander A., Reid K.B., et al. Deficient hydrophilic lung surfactant proteins A and D with normal surfactant phospholipid molecular species in cystic fibrosis. Am J Respir Cell Mol Biol 1999, 20(1):90-98.
65. Woodworth B.A., Lathers D., Neal J.G., et al. Immunolocalization of surfactant protein A and D in sinonasal mucosa. Am J Rhinol 2006, 20(4):461-465.
66. Woodworth B.A., Wood R., Baatz J.E., et al. Sinonasal surfactant protein A1, A2, and D gene expression in cystic fibrosis: a preliminary report. Otolaryngol Head Neck Surg 2007, 137(1):34-38.
67. Skinner M.L., Schlosser R.J., Lathers D., et al. Innate and adaptive mediators in cystic fibrosis and allergic fungal rhinosinusitis. Am J Rhinol 2007, 21(5):538-541.
68. Psaltis A.J., Weitzel E.K., Ha K.R., et al. The effect of bacterial biofilms on post-sinus surgical outcomes. Am J Rhinol 2008, 22(1):1-6.
69. Healy D.Y., Leid J.G., Sanderson A.R., et al. Biofilms with fungi in chronic rhinosinusitis. Otolaryngol Head Neck Surg 2008, 138(5):641-647.
70. Prince A.A., Steiger J.D., Khalid A.N., et al. Prevalence of biofilm-forming bacteria in chronic rhinosinusitis. Am J Rhinol 2008, 22(3):239-245.
71. Ha K.R., Psaltis A.J., Butcher A.R., et al. In vitro activity of mupirocin on clinical isolates of Staphylococcus aureus and its potential implications in chronic rhinosinusitis. Laryngoscope 2008, 118(3):535-540.
72. Alandejani T., Marsan J., Ferris W., et al. Effectiveness of honey on Staphylococcus aureus and Pseudomonas aeruginosa biofilms. Otolaryngol Head Neck Surg 2009, 141(1):114-118.
73. Lim M., Citardi M.J., Leong J.L. Topical antimicrobials in the management of chronic rhinosinusitis: a systematic review. Am J Rhinol 2008, 22(4):381-389.
74. Uren B., Psaltis A., Wormald P.J. Nasal lavage with mupirocin for the treatment of surgically recalcitrant chronic rhinosinusitis. Laryngoscope 2008, 118(9):1677-1680.
75. Elliott K.A., Stringer S.P. Evidence-based recommendations for antimicrobial nasal washes in chronic rhinosinusitis. Am J Rhinol 2006, 20(1):1-6.
76. Chiu A.G., Antunes M.B., Palmer J.N., et al. Evaluation of the in vivo efficacy of topical tobramycin against Pseudomonas sinonasal biofilms. J Antimicrob Chemother 2007, 59(6):1130-1134.
77. Chennupati S.K., Chiu A.G., Tamashiro E., et al. Effects of an LL-37-derived antimicrobial peptide in an animal model of biofilm Pseudomonas sinusitis. Am J Rhinol Allergy 2009, 23(1):46-51.
78. Antunes M.B., Feldman M.D., Cohen N.A., et al. Dose-dependent effects of topical tobramycin in an animal model of Pseudomonas sinusitis. Am J Rhinol 2007, 21(4):423-427.
79. Geller D.E. Aerosol antibiotics in cystic fibrosis. Respir Care 2009, 54(5):658-670.
80. Ebbens F.A., Scadding G.K., Badia L., et al. Amphotericin B nasal lavages: Not a solution for patients with chronic rhinosinusitis. J Allergy Clin Immunol 2006, 118(5):1149-1156.
81. Le T., Psaltis A., Tan L.W., et al. The efficacy of topical antibiofilm agents in a sheep model of rhinosinusitis. Am J Rhinol 2008, 22(6):560-567.
82. Nijnik A., Hancock R.E. The roles of cathelicidin LL-37 in immune defenses and novel clinical applications. Curr Opin Hematol 2009, 16(1):41-47.
83. Overhage J., Campisano A., Bains M., et al. Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect Immun 2008, 76(9):4176-4182.
84. Lau Y.E., Bowdish D.M., Cosseau C., et al. Apoptosis of airway epithelial cells: human serum sensitive induction by the cathelicidin LL-37. Am J Respir Cell Mol Biol 2006, 34(4):399-409.
85. Psaltis A.J., Ha K.R., Beule A.G., et al. Confocal scanning laser microscopy evidence of biofilms in patients with chronic rhinosinusitis. Laryngoscope 2007, 117(7):1302-1306.
86. Ha K.R., Psaltis A.J., Tan L., et al. A sheep model for the study of biofilms in rhinosinusitis. Am J Rhinol 2007, 21(3):339-345.
87. Vonk M.J., Hiemstra P.S., Grote J.J. An antimicrobial peptide modulates epithelial responses to bacterial products. Laryngoscope 2008, 118(5):816-820.
88. Singh P.K., Parsek M.R., Greenberg E.P., et al. A component of innate immunity prevents bacterial biofilm development. Nature 2002, 417(6888):552-555.
89. Farnaud S., Evans R.W. Lactoferrin-a multifunctional protein with antimicrobial properties. Mol Immunol 2003, 40(7):395-405.
90. Psaltis A.J., Wormald P.J., Ha K.R., et al. Reduced levels of lactoferrin in biofilm-associated chronic rhinosinusitis. Laryngoscope 2008, 118(5):895-901.
91. Raphael G.D., Jeney E.V., Baraniuk J.N., et al. Pathophysiology of rhinitis. Lactoferrin and lysozyme in nasal secretions. J Clin Invest 1989, 84(5):1528-1535.
92. Fukami M., Stierna P., Veress B., et al. Lysozyme and lactoferrin in human maxillary sinus mucosa during chronic sinusitis. An immunohistochemical study. Eur Arch Otorhinolaryngol 1993, 250(3):133-139.
93. Ellison R.T., Giehl T.J. Killing of gram-negative bacteria by lactoferrin and lysozyme. J Clin Invest 1991, 88(4):1080-1091.
94. Anil S., Samaranayake L.P. Impact of lysozyme and lactoferrin on oral Candida isolates exposed to polyene antimycotics and fluconazole. Oral Dis 2002, 8(4):199-206.
95. Samaranayake Y.H., Cheung B.P., Parahitiyawa N., et al. Synergistic activity of lysozyme and antifungal agents against Candida albicans biofilms on denture acrylic surfaces. Arch Oral Biol 2009, 54(2):115-126.
96. Tewfik M.A., Latterich M., DiFalco M.R., et al. Proteomics of nasal mucus in chronic rhinosinusitis. Am J Rhinol 2007, 21(6):680-685.
97. Lee H., Churey J.J., Worobo R.W. Antimicrobial activity of bacterial isolates from different floral sources of honey. Int J Food Microbiol 2008, 126(1-2):240-244.